Seven Eight Capital, LP Amylyx Pharmaceuticals, Inc. Transaction History

Seven Eight Capital, LP

  • $1.05 Billion
  • Q3 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 13, 2024
BUY
$12.07 - $18.46 $83,403 - $127,558
6,910 Added 11.54%
66,801 $983,000
Q3 2023

Nov 14, 2023
BUY
$18.08 - $23.45 $1.08 Million - $1.4 Million
59,891 New
59,891 $1.1 Million
Q1 2023

May 12, 2023
BUY
$27.71 - $40.93 $418,836 - $618,656
15,115 Added 101.18%
30,053 $881,000
Q4 2022

Feb 13, 2023
BUY
$29.75 - $39.26 $85,561 - $112,911
2,876 Added 23.84%
14,938 $551,000
Q3 2022

Nov 10, 2022
BUY
$17.15 - $30.92 $206,863 - $372,957
12,062 New
12,062 $340,000

Others Institutions Holding AMLX

# of Institutions
127
Shares Held
44.4M
Call Options Held
235K
Put Options Held
530K
View Full List

About Amylyx Pharmaceuticals, Inc.

AMLX Quotes by TradingView
  • Ticker AMLX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,533,200
  • Market Cap $310M
  • Description
  • Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...
More about AMLX
Track This Portfolio

Track Seven Eight Capital, LP Portfolio

Follow Seven Eight Capital, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Seven Eight Capital, LP, based on Form 13F filings with the SEC.

News

Stay updated on Seven Eight Capital, LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email